Browse studies

Find your next paid study

617 recruiting studies matching your filters

Improving Communication With and Building a Stronger Medical Home Among Spanish-speaking Families in the Center for Cancer and Blood Disorders

This study will seek to improve communication with Spanish speaking families and patients with Cancer and Blood Disorders.

LeukemiaNon Hodgkin Lymphoma

Estimated

~$10 – $750

University of Colorado, DenverNCT05425992

Observational

Pilot Randomized Controlled Trial of a Remote Monitoring and Symptom Management Intervention (ASSIST) Among Patients Receiving Systemic Therapy

The goal of this clinical trial is to learn if an artificial intelligence phone application called ASSIST can help patients receiving cancer treatment. The ma…

Breast Cancer (Locally Advanced or Metastatic)LymphomaColorectal Cancer

Estimated

~$10 – $7,500

Patrick C. Johnson, MDNCT07553572

Phase 1

A Phase 1b/2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies

This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. r…

Advanced CancerAdvanced Solid TumorMelanoma+15 more

Estimated

~$10 – $8,750

7 Hills Pharma, LLCNCT06362369

Phase 1

A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients wit…

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+5 more

Estimated

~$10 – $8,750

Nurix Therapeutics, Inc.NCT04830137

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell P…

Peripheral T-Cell Lymphoma

Estimated

~$10 – $1,125

Associazione Angela Serra per la ricerca sul cancroNCT03964480

Phase 2

A Phase 2 Study of Epcoritamab as a Consolidation Therapy for 2nd Generation BTKi +/- Obinutuzumab in CLL/SLL Patients or Variants of This.

This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of thi…

CLL/SLLCLLSLL+4 more

Estimated

~$10 – $7,500

Zulfa OmerNCT07108998

Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-Cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors (HALT) - A Pilot Study

This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.

Chronic Lymphocytic LeukemiaHematopoietic and Lymphoid System NeoplasmMantle Cell Lymphoma+2 more

Estimated

~$10 – $750

Mayo ClinicNCT06151730

Phase 1

Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)

This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the stu…

Cutaneous T Cell LymphomaMycosis Fungoides

Estimated

~$10 – $6,250

University of Alabama at BirminghamNCT05414500

Phase 1

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

The study participant has one of the following blood cancers: acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (B-…

Hematologic MalignancyALL, ChildhoodAML, Childhood+2 more

Estimated

~$10 – $6,250

St. Jude Children's Research HospitalNCT06326463

Phase 1

A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas

A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dos…

Triple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular Lymphoma+11 more

Estimated

~$10 – $8,750

OncoNano Medicine, Inc.NCT06022029

Phase 1

Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy: A First in Human Randomized Pilot Study. Neuromodulation in Cancer Study (OU-SCC-NCAN)

This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain …

Breast CancerLymphoma

Estimated

~$10 – $6,250

University of OklahomaNCT05921253

Describing Treatment Outcomes and Responses in Lymphoma-associated Hemophagocytic Lymphohistiocytosis

The purpose of the study is to describe Hemophagocytic lymphohistiocytosis (HLH) in patients with lymphoma to identify possible therapeutic strategies to impro…

LymphomaHemophagocytic Lymphohistiocytoses

Estimated

~$10 – $750

University of Alabama at BirminghamNCT05898477